Journal of Biological Chemistry,
Год журнала:
2023,
Номер
299(8), С. 104975 - 104975
Опубликована: Июль 8, 2023
Diabetes
mellitus
is
the
leading
cause
of
cardiovascular
and
renal
disease
in
United
-States.
Despite
beneficial
interventions
available
for
patients
with
diabetes,
there
remains
a
need
additional
therapeutic
targets
therapies
diabetic
kidney
(DKD).
Inflammation
oxidative
stress
are
increasingly
recognized
as
important
causes
diseases.
closely
associated
mitochondrial
damage.
The
molecular
connection
between
inflammation
metabolism
to
be
elucidated.
Recently,
nicotinamide
adenine
nucleotide
(NAD+)
has
been
found
regulate
immune
function
inflammation.
In
present
studies,
we
tested
hypothesis
that
enhancing
NAD
could
prevent
progression
DKD.
We
treatment
db/db
mice
type
2
diabetes
riboside
(NR)
prevented
several
manifestations
dysfunction
(i.e.,
albuminuria,
increased
urinary
injury
marker-1
(KIM1)
excretion,
pathologic
changes).
These
effects
were
decreased
inflammation,
at
least
part
via
inhibiting
activation
cyclic
GMP-AMP
synthase-stimulator
interferon
genes
(cGAS-STING)
signaling
pathway.
An
antagonist
serum
stimulator
(STING)
whole-body
STING
deletion
showed
similar
renoprotection.
Further
analysis
NR
SIRT3
activity
improved
function,
which
led
DNA
damage,
trigger
leakage
activates
cGAS-STING
Overall,
these
data
show
supplementation
boosted
augment
reducing
thereby
preventing
disease.
Nicotinamide
riboside
is
a
precursor
to
the
important
cofactor
nicotinamide
adenine
dinucleotide
and
has
elicited
metabolic
benefits
in
multiple
preclinical
studies.
In
2016,
first
clinical
trial
of
was
conducted
test
safety
efficacy
human
supplementation.
Many
trials
have
since
been
aiming
delineate
health
severe
diseases
humans.
This
review
endeavors
summarize
critically
assess
25
currently
published
research
articles
on
supplementation
identify
any
poorly
founded
claims
assist
field
elucidating
actual
future
potential
for
riboside.
Collectively,
oral
displayed
few
clinically
relevant
effects,
there
an
unfortunate
tendency
literature
exaggerate
importance
robustness
reported
effects.
Even
so,
may
play
role
reduction
inflammatory
states
shown
some
treatment
diverse
diseases.
Biomedicines,
Год журнала:
2023,
Номер
11(7), С. 1903 - 1903
Опубликована: Июль 5, 2023
Civilization
diseases
are
defined
as
non-communicable
that
affect
a
large
part
of
the
population.
Examples
such
depression
and
cardiovascular
disease.
Importantly,
World
Health
Organization
warns
against
an
increase
in
both
these.
This
narrative
review
aims
to
summarize
available
information
on
measurable
risk
factors
for
CVD
based
existing
literature.
The
paper
reviews
epidemiology
main
coexistence
authors
emphasize
there
is
evidence
link
between
Here,
we
highlight
common
disease,
including
obesity,
diabetes,
physical
inactivity,
well
importance
prevention
treatment
preventing
other
mental
disorders.
Conversely,
effective
can
also
help
prevent
improve
health
outcomes.
It
seems
advisable
introduce
screening
tests
patients
treated
cardiac
reasons.
mood
disorders,
it
worth
controlling
factors,
example,
by
checking
blood
pressure
pulse
during
routine
visits.
paying
attention
condition
with
CVD.
study
underlines
interdisciplinary
co-operation.
Journal of Neurochemistry,
Год журнала:
2024,
Номер
168(5), С. 910 - 954
Опубликована: Янв. 6, 2024
Although
we
have
learned
much
about
how
the
brain
fuels
its
functions
over
last
decades,
there
remains
still
to
discover
in
an
organ
that
is
so
complex.
This
article
lays
out
major
gaps
our
knowledge
of
interrelationships
between
metabolism
and
function,
including
biochemical,
cellular,
subcellular
aspects
functional
imaging
adult
brain,
as
well
during
development,
aging,
disease.
The
focus
on
unknowns
substrates
associated
transporters,
roles
insulin
lipid
droplets,
emerging
role
microglia,
mysteries
cofactor
signaling
molecule
NAD
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Июнь 7, 2024
Abstract
Objective
Sodium
glucose
cotransporter
2
(SGLT2)
inhibitors
significantly
improve
cardiovascular
outcomes
in
diabetic
patients;
however,
the
mechanism
is
unclear.
We
hypothesized
that
dapagliflozin
improves
cardiac
via
beneficial
effects
on
systemic
and
inflammation
fibrosis.
Research
design
methods
This
randomized
placebo-controlled
clinical
trial
enrolled
62
adult
patients
(mean
age
62,
17%
female)
with
type
diabetes
(T2D)
without
known
heart
failure.
Subjects
were
to
12
months
of
daily
10
mg
or
placebo.
For
all
patients,
blood/plasma
samples
magnetic
resonance
imaging
(CMRI)
obtained
at
time
randomization
end
months.
Systemic
was
assessed
by
plasma
IL-1B,
TNFα,
IL-6
ketone
levels
PBMC
mitochondrial
respiration,
an
emerging
marker
sterile
inflammation.
Global
myocardial
strain
feature
tracking;
fibrosis
T1
mapping
calculate
extracellular
volume
fraction
(ECV);
tissue
T2
mapping.
Results
Between
baseline
12-month
point,
IL-1B
reduced
(−
1.8
pg/mL,
P
=
0.003)
while
ketones
increased
(0.26
mM,
0.0001)
dapagliflozin.
maximal
oxygen
consumption
rate
(OCR)
decreased
over
period
placebo
group
but
did
not
change
receiving
158.9
pmole/min/10
6
cells,
0.0497
vs.
−
5.2
0.41),
a
finding
consistent
anti-inflammatory
effect
SGLT2i.
strain,
ECV
relaxation
both
study
groups.
Clinical
Trial.gov
Registration
NCT03782259.
Circulation Research,
Год журнала:
2025,
Номер
136(5), С. 524 - 550
Опубликована: Фев. 27, 2025
Cardiovascular
diseases
(CVDs)
are
experiencing
a
rapid
surge
and
widely
recognized
as
the
leading
cause
of
mortality
in
current
aging
society.
Given
multifactorial
etiology
CVDs,
understanding
intricate
molecular
cellular
mechanisms
is
imperative.
Over
past
2
decades,
many
scientists
have
focused
on
Sirtuins,
family
nicotinamide
adenine
dinucleotide–dependent
deacylases.
Sirtuins
highly
conserved
across
species,
from
yeasts
to
primates,
play
crucial
role
linking
diseases.
participate
nearly
all
key
physiological
pathological
processes,
ranging
embryogenic
development
stress
response
aging.
Abnormal
expression
activity
exist
aging-related
diseases,
while
their
activation
has
shown
efficacy
mitigating
these
(eg,
CVDs).
In
terms
research,
this
field
maintained
fast,
sustained
growth
recent
years,
fundamental
studies
clinical
trials.
review,
we
present
comprehensive,
up-to-date
discussion
biological
functions
roles
regulating
cardiovascular
biology
CVDs.
Furthermore,
highlight
latest
advancements
utilizing
Sirtuin-activating
compounds
dinucleotide
boosters
potential
pharmacological
targets
for
preventing
treating
The
unresolved
issues
field—from
chemicobiological
regulation
Sirtuin-targeted
CVD
investigations—are
also
discussed.
This
timely
review
could
be
critical
updated
knowledge
Sirtuin
CVDs
facilitating
accessibility
Sirtuin-targeting
interventions.
Frontiers in Molecular Biosciences,
Год журнала:
2021,
Номер
7
Опубликована: Янв. 29, 2021
The
Nobel
Prize-deserving
concept
of
blocking
inhibitory
pathways
in
T
cells,
to
unleash
their
anti-tumoral
capacity,
became
one
the
pillars
cancer
treatment
last
decade
and
has
resulted
durable
clinical
responses
for
multiple
types.
Currently,
two
most
important
goals
immunotherapy
are
understand
mechanisms
resulting
failure
checkpoint
blockade
identify
predictive
immunological
biomarkers
that
correlate
response,
disease
progression
or
adverse
effects.
identification
validation
routine
use
is
not
only
critical
monitor
progression,
but
also
personalize
develop
new
therapies.
To
achieve
these
goals,
powerful
research
tools
needed.
Flow
cytometry
stands
as
successful
single-cell
analytical
used
characterize
immune
cell
phenotypes
solid
tumors,
hematological
malignancies,
minimal
residual
metastatic
progression.
This
technology
been
fundamental
diagnosis,
translational
trials.
Most
recently,
need
evaluate
simultaneously
more
features
each
pushed
field
implement
adaptations
beyond
conventional
flow
cytometry,
including
Full
Spectrum
Cytometry
(FSFC).
FSFC
captures
full
emission
spectrum
fluorescent
molecules
using
arrays
highly
sensitive
light
detectors,
date
enabled
characterization
40
parameters
a
single
sample.
We
will
summarize
contributions
this
advancement
studies
discuss
best
practices
obtain
reliable,
robust
reproducible
results.
Circulation,
Год журнала:
2021,
Номер
144(22), С. 1795 - 1817
Опубликована: Ноя. 29, 2021
Nicotinamide
adenine
dinucleotide
(NAD
+
)
is
a
central
metabolite
involved
in
energy
and
redox
homeostasis
as
well
DNA
repair
protein
deacetylation
reactions.
Pharmacological
or
genetic
inhibition
of
NAD
-degrading
enzymes,
external
supplementation
precursors,
transgenic
overexpression
-generating
enzymes
have
wide
positive
effects
on
metabolic
health
age-associated
diseases.
pools
tend
to
decline
with
normal
aging,
obesity,
hypertension,
which
are
all
major
risk
factors
for
cardiovascular
disease,
replenishment
extends
healthspan,
avoids
syndrome,
reduces
blood
pressure
preclinical
models.
In
addition,
experimental
elevation
improves
atherosclerosis,
ischemic,
diabetic,
arrhythmogenic,
hypertrophic,
dilated
cardiomyopathies,
different
modalities
heart
failure.
Here,
we
critically
discuss
cardiomyocyte-specific
circuitries
metabolism,
comparatively
evaluate
distinct
precursors
their
efficacy,
raise
outstanding
questions
the
optimal
design
clinical
trials
supraphysiological
elevations
assessed
prevention
treatment
cardiac
We
surmise
that
patients
hitherto
intractable
diseases
such
failure
preserved
ejection
fraction
may
profit
from
administration
precursors.
The
development
-centered
treatments
will
rely
technological
conceptual
progress
fine
regulation
metabolism.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(24), С. 16053 - 16053
Опубликована: Дек. 16, 2022
High
mortality
rates
due
to
cardiovascular
diseases
(CVDs)
have
attracted
worldwide
attention.
It
has
been
reported
that
mitochondrial
dysfunction
is
one
of
the
most
important
mechanisms
affecting
pathogenesis
CVDs.
Mitochondrial
DNA
(mtDNA)
mutations
may
result
in
impaired
oxidative
phosphorylation
(OXPHOS),
abnormal
respiratory
chains,
and
ATP
production.
In
dysfunctional
mitochondria,
electron
transport
chain
(ETC)
uncoupled
energy
supply
reduced,
while
reactive
oxygen
species
(ROS)
production
increased.
Here,
we
discussed
analyzed
relationship
between
mtDNA
mutations,
mitophagy,
decreased
OXPHOS,
elevated
ROS,
CVDs
from
perspective
dysfunction.
Furthermore,
explored
current
potential
therapeutic
strategies
for
by
eliminating
(e.g.,
editing
replacement),
enhancing
improving
OXPHOS
capacity
supplement
with
NAD+,
nicotinamide
riboside
(NR),
mononucleotide
(NMN),
nano-drug
delivery),
reducing
ROS
Coenzyme
Q10
other
antioxidants),
dissected
their
respective
advantages
limitations.
fact,
some
are
still
a
long
way
achieving
safe
effective
clinical
treatment.
Although
establishing
remains
challenging,
starting
holds
bright
prospects.
Frontiers in Nutrition,
Год журнала:
2022,
Номер
9
Опубликована: Апрель 11, 2022
Nicotinamide
mononucleotide
(NNM)
is
an
orally
bioavailable
NAD+
precursor
that
has
demonstrated
beneficial
effects
against
aging
and
aging-associated
diseases
in
animal
models.
NMN
ultimately
converted
to
NAD+,
a
redox
cofactor
mediates
many
metabolic
enzymes.
also
serves
as
the
substrate
for
poly(ADP-ribose)
polymerase
(PARP)
sirtuins,
regulates
various
biological
processes,
such
metabolism,
DNA
repair,
gene
expression,
stress
responses.
Previous
mouse
models
showed
administration
can
increase
organs
ameliorate
aging-related
diseases,
obesity,
diabetes,
heart
failure,
stroke,
kidney
Alzheimer's
disease
through
NAD+-mediated
pathways.
However,
evidence
of
its
effect
on
humans
still
scarce.
In
this
study,
we
conducted
placebo-controlled,
randomized,
double
blind,
parallel-group
trial
investigate
safety
administered
efficacy
levels
thirty
healthy
subjects.
Healthy
volunteers
received
250
mg/day
(n
=
15)
or
placebo
12
weeks,
physiological
laboratory
tests
were
performed
during
period.
addition,
related
metabolites
whole
blood
examined.
Oral
supplementation
weeks
caused
no
abnormalities
tests,
obvious
adverse
observed.
significantly
increased
after
administration.
We
observed
significant
rise
nicotinic
acid
(NAMN)
levels,
but
not
NMN.
found
amount
was
strongly
correlated
with
pulse
rate
before
These
results
suggest
oral
safe
practical
strategy
boost
humans.
Clinical
Trial
Registration:
JRCT
[https://jrct.niph.go.jp/],
identifier:
[jRCTs041200034].